4760 Results

People

  1. Berger
    Berger
  2. Motzer
    Motzer
  3. Giralt
    Giralt
  4. Perales
    Perales
  5. Lee
    Lee
  6. Hudis
    Hudis
  7. Morrow
    Morrow
  8. Levine
    Levine
  9. Reis-Filho
    Reis-Filho
  10. Solit
    Solit

Groups

  1. Department of Medicine (1963)
  2. GSK Faculty (1162)
  3. Solid Tumor Oncology Division (1064)
  4. Surgery (904)
  5. Survivorship Research (795)
  6. Center for Hematologic Malignancies (777)
  7. Sloan Kettering Institute Postdocs (739)
  8. Hematologic Malignancies, Division of (725)
  9. Department of Pathology and Laboratory Medicine (655)
  10. Population Sciences Research Program (574)
  1. "2016"
Formats
  1. Journal Article (2949)
  2. Meeting Abstract (1606)
  3. Book Section (155)
  4. Conference Paper (36)
  5. Book Whole (14)
Groups
  1. Department of Medicine (1963)
  2. GSK Faculty (1162)
  3. Solid Tumor Oncology Division (1064)
  4. Surgery (904)
  5. Survivorship Research (795)
  6. Center for Hematologic Malignancies (777)

More Groups

People
  1. Michael Berger (93)
  2. Jedd Wolchok (84)
  3. Robert Motzer (74)
  4. Sergio Giralt (73)
  5. Miguel-Angel Perales (69)
  6. Jose Baselga (67)

More People

Years
  1. 2016 (4760)
Publications
  1. Journal of Clinical Oncology (469)
  2. Blood (210)
  3. Modern Pathology (124)
  4. Laboratory Investigation (108)
  5. International Journal of Radiation Oncology, Biology, Physics (104)
  6. Annals of Oncology (94)

More Publications

Publishers
  1. Elsevier Inc. (519)
  2. American Society of Clinical Oncology (497)
  3. Springer (349)
  4. Nature Publishing Group (322)
  5. Oxford University Press (248)
  6. American Society of Hematology (213)

More Publishers

Results (4760)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers
    Meeting Abstract

    Somwar, R.; Smith, R.; Hayashi, T.; Ishizawa, K.; Charen, A. S.; Khodos, I.; Mattar, M.; He, J.; Balasubramanian, S.; Stephens, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A patient safety approach to assessing adverse events in oncology: Results from CHARM (Cancer Harm) study
    Meeting Abstract

    Lipitz Snyderman, A. N.; Classen, D.; Pfister, D. G.; Killen, A.; Epstein, A. S.; Anderson, C. B.; Atoria, C. L.; Fortier, E.; Weingart, S. N.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Off-label use of bevacizumab in relapsed and refractory pediatric sarcoma patients: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Slotkin, E. K.; Magnan, H. D.; Meyers, P. A.; Chou, A. J.; Ambati, S. R.; Wexler, L. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma
    Meeting Abstract

    Shoushtari, A. N.; Kudchadkar, R. R.; Panageas, K.; Murthy, R. K.; Jung, M.; Shah, R.; O'Donnell, B.; Khawaja, T. T.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Radiation therapy and low dose doxorubicin in thyroid cancer: A phase II study
    Meeting Abstract

    Sherman, E. J.; Romesser, P. B.; Ho, A. L.; Baxi, S. S.; Riaz, N.; McBride, S. M.; Chan, S.; Tuttle, R. M.; Pfister, D. G.; Lee, N. Y.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Complex association between social support and chemotherapy-related toxicities in older cancer patients
    Meeting Abstract

    Shahrokni, A.; Sun, C.; Tew, W. P.; Mohile, S. G.; Owusu, C.; Klepin, H. D.; Gross, C. P.; Lichtman, S. M.; Gajra, A.; Katheria, V.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Sequist, L. V.; Anderson, I. C.; Demars, N.; Felip, E.; Harb, W. A.; Huber, R. M.; Kudla, A. J.; Lee, J. K.; Mathews, S.; McClure, T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save